PAD4
PADI4proteinEnzyme mediating neutrophil extracellular trap formation, amplifying plaque inflammation and thrombotic burden.
Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationalePeptidylarginine deiminase catalyzing histone citrullination and NET formation.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000159339
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I67
C — confounder / Type-II70
A — assay feasibility68
E — evidence strength29
T1DI (composite)10
Specificity differential (R−C)-2.8
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Costunolide Reduces DN Inflammatory Response and Renal Thrombosis by Inhibiting NET Formation.Journal of diabetes research · 2025 · PMID 40709100 · doi
- Neutrophil Extracellular Traps (NETs) in health and disease.Molecular biomedicine · 2025 · PMID 41335221 · doi